Dihexa

Mechanism

Evidence tier: 4 — Mechanism characterized in cell-culture and rodent behavioral studies. The original mechanism paper has been formally retracted; mechanism is provisional.

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, also designated PNB-0408) is a synthetic six-carbon-modified dipeptide derivative of Angiotensin IV developed at Washington State University by the Harding laboratory. The molecule was engineered as an orally bioavailable, blood-brain-barrier-permeable analog of the larger Angiotensin IV peptide, with the goal of accessing the cognitive-enhancing and neurogenic effects observed with central Angiotensin IV in animal models.

The proposed mechanism is HGF/c-Met receptor system activation. The McCoy 2013 (PMID 23055539) and Benoist 2014 (PMID 25187433) papers reported that Dihexa binds hepatocyte growth factor (HGF) and allosterically enhances HGF binding to its receptor c-Met, leading to c-Met phosphorylation and downstream signaling. The downstream effect is hippocampal spinogenesis and synaptogenesis — an increase in dendritic spine density and synaptic markers in hippocampal neurons, supporting the procognitive behavioral signals in rodent learning tasks.

Important caveat about the mechanism literature: The Benoist 2014 paper that established the HGF/c-Met mechanism was formally retracted in 2025 after data-integrity concerns; the McCoy 2013 paper received an expression of concern but remained published. This retraction does not necessarily mean Dihexa is ineffective — the behavioral effects in animal models have been replicated in other publications — but it does mean the specific mechanism-of-action claim should be treated as provisional rather than established. The molecule's procognitive signal in animals may operate through a different or additional mechanism than the HGF/c-Met pathway that the retracted work characterized.

Typical protocols

Evidence tier: 5 — No human RCTs. All protocols are animal-derived extrapolations or community-evolved.

There are no published human clinical trials of Dihexa as of May 2026. Frame protocols accordingly.

The rodent-model dosing in McCoy 2013 used oral Dihexa at 2 mg/kg to reverse scopolamine-induced cognitive deficits in Morris water maze tasks. Community-circulated human protocols extrapolate from this with no validated translation — typical reported doses are 5-15 mg orally per day, sometimes in cycles, sometimes continuously. The oral bioavailability that distinguishes Dihexa from most peptides is the basis for the popularity of oral dosing protocols in the nootropic community.

Reported community use frames Dihexa as a hippocampus-targeted cognition enhancer for "neurogenesis cycles" of 4-8 weeks. No validated human dose exists, no human pharmacokinetic data exists, and no human safety threshold has been characterized. Patients considering Dihexa should treat this as a pre-clinical research molecule rather than a usable therapeutic.

Evidence by indication

Evidence tier: 3 — Rodent behavioral and synaptogenesis evidence; zero human RCT evidence.

Cognition (rodent learning models): McCoy 2013 (PMID 23055539) showed oral Dihexa reversed scopolamine-induced cognitive deficits in rats over 7 days of dosing. Multiple subsequent rodent learning studies have replicated procognitive signals in normal and impaired animals.

Synaptogenesis and dendritic spine density (cell culture, rodent): Hippocampal dendritic spine density increases with Dihexa exposure in cell culture and in treated animals. The synaptogenic effect is reasonably robust across multiple in-vitro and in-vivo studies, though the mechanism explanation is now provisional given the Benoist 2014 retraction.

Alzheimer's disease models (rodent): Treatment of rodent Alzheimer's models with Dihexa has shown cognitive and synaptic improvements in several published studies. The translational implications are conjectural until human studies are conducted.

Hair-cell protection: A separate body of work has shown HGF-mimetic Dihexa-related compounds protect lateral-line hair cells from aminoglycoside damage in zebrafish models — an entirely separate indication from the cognitive work.

Human evidence: None. Dihexa has not entered formal clinical development. There is no IND, no Phase 1 trial, no FDA orphan-drug designation. The molecule is sourced exclusively through research-supplier channels.

The honest framing: Dihexa has interesting rodent cognitive data but the molecule is pre-clinical, the foundational mechanism paper has been retracted, and the absence of any human safety or efficacy data places it firmly in research-context territory rather than usable-therapeutic territory.

Safety profile

Evidence tier: 4 — Rodent safety data; zero human safety characterization.

In published rodent studies, Dihexa was generally well-tolerated at therapeutic doses with no acute toxicity reported. The molecule has not been systematically dose-escalated in any species for chronic-toxicity characterization. There is no human safety data.

Theoretical concerns include:

1. Off-target effects on c-Met signaling: c-Met is a proto-oncogenic receptor implicated in several cancer types. Sustained pharmacological activation of c-Met signaling raises a theoretical oncogenic concern that has not been characterized in any model. 2. HGF-pathway effects in non-CNS tissues: HGF and c-Met are expressed throughout the body; CNS-targeted effects may be accompanied by hepatic, renal, or vascular off-target activity. 3. Long-term hippocampal synaptogenesis: The chronic-dosing safety profile of sustained synaptogenic stimulation is not characterized. 4. Research-supplier purity: As an unregulated peptide, sourcing variability and contamination are real concerns.

The retraction of the Benoist 2014 mechanism paper also complicates safety reasoning — if the mechanism of action is not fully characterized, off-target effects are harder to predict.

Where it fits relative to alternatives

Evidence tier: 5 — Editorial positioning.

In the cognitive-enhancement and neurotrophic-peptide landscape:

• Cerebrolysin: Substantial RCT data in stroke, dementia, TBI; injectable, expensive.
• Semax: Russian peptide nootropic with intranasal delivery and some clinical data.
• P21: CNTF-derived hippocampal-neurogenesis peptide with primarily rodent data.
• Dihexa: HGF-pathway peptide with rodent data only and a retracted foundational mechanism paper.

For validated cognitive-enhancement intervention, the FDA-approved options remain donepezil/rivastigmine/memantine (cholinesterase inhibitors, NMDA modulator) and aducanumab/lecanemab (amyloid-targeting antibodies in early Alzheimer's). Within the peptide nootropic class, Cerebrolysin has substantially more RCT data than Dihexa. Within the neurogenesis-targeting peptide subclass, P21 and Dihexa are comparable in being pre-clinical with promising rodent data — the Cerebrolysin vs P21 comparison frames the broader pre-clinical-vs-clinical positioning.

Dihexa's specific positioning is research-context exploration of HGF-pathway cognitive modulation, not a validated therapeutic.

Regulatory status + access

Evidence tier: 5 — Regulatory-process content.

Dihexa is not FDA-approved for any indication, not on the FDA bulks list for 503A or 503B compounding, and is not lawfully available through US compounding pharmacy channels. The molecule has not entered formal clinical development — no IND, no Phase 1 trial, no FDA designations. Research-supplier access exists but operates outside any clinical evidence base. WADA does not list Dihexa specifically. The retraction of the foundational mechanism paper is a regulatory-relevant signal that the molecule's pre-clinical research base is less solid than the broader Dihexa marketing literature suggests. Patients considering Dihexa should discuss the molecule's pre-clinical status with a clinician and treat it as a research compound rather than a therapeutic.

References

• McCoy AT, Benoist CC, Wright JW, et al. 2013. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. J Pharmacol Exp Ther. PMID 23055539 — note: expression of concern issued.
• Benoist CC, Kawas LH, Zhu M, et al. 2014. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system. J Pharmacol Exp Ther. PMID 25187433 — note: retracted in 2025 for data-integrity concerns.
• Blanchard J, Chohan MO, Li B, et al. 2010. Beneficial effect of a CNTF tetrapeptide on adult hippocampal neurogenesis, neuronal plasticity, and spatial memory in mice. J Alzheimers Dis. PMID 20952820 — cited as comparator for pre-clinical neurogenic peptide research methodology.

Limitations

This page does not constitute medical advice. Dihexa sits in a pre-clinical research-context category with the additional complication that the foundational mechanism paper has been retracted. There are no human RCTs, no human dose-response data, no characterized human safety profile, and no FDA-approved pathway. Patients pursuing Dihexa through research-supplier channels are operating outside any clinical evidence base, and the molecule should not be framed as a treatment for cognitive impairment, Alzheimer's disease, or any specific indication. The theoretical oncogenic concern from sustained c-Met pathway activation is unresolved. We would update our framing if Dihexa enters formal clinical development, if independent replication confirms the HGF/c-Met mechanism, or if any meaningful human pharmacokinetic or safety data is published.